Glenmark Pharmaceuticals receives USFDA clearance for IND application for GSP 304

08 Mar 2017 Evaluate

Glenmark Pharmaceuticals, a global pharmaceutical company, has received US Food and Drug Administration (USFDA) clearance for its Investigational New Drug (IND) application to begin a Phase 2 study of GSP 304 (tiotropium bromide) for administration by nebulization for the long term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).

The company plans to initiate clinical development with a Phase 2 study of GSP 304, a new orally administered formulation, in subjects with mild to moderate COPD, as determined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The efficacy, pharmacokinetics, and safety profiles of currently available formulations of tiotropium bromide are well established.

Glenmark Pharmaceuticals is a global innovative pharmaceutical company with operations in more than 80 countries. It has a diverse pipeline with several compounds in various stages of clinical development primarily focused in the areas of oncology, respiratory disease, and dermatology.


 

Glenmark Pharma Share Price

1946.50 -19.55 (-0.99%)
17-Dec-2025 10:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1772.55
Dr. Reddys Lab 1269.10
Cipla 1491.50
Zydus Lifesciences 914.75
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×